Viscient Biosciences

"When I was at Amgen, Inc. , Roger Perlmutter [executive VP and head of R&D] used to say: 'We need to move things forward quickly, because the real experiments are in humans.' " In this podcast, In

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer , Bayer ’s former chief digital officer a

The second quarter of 2023 was a good news bad news situation for venture capital investment in biopharmaceutical companies, according to the latest Venture Monitor report from Pitchbook and the Natio

This year began with the expectation of the first drug approval in non-alcoholic steatohepatitis, with a number of other Phase III programs right on the lead product’s heels. But instead, the year is